Wound Care Innovations, LLC, a subsidiary of Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM - News), announced today that it will attend and exhibit at the Wound Care Seminar: Clinical and Economical Realities in Boston. This seminar is presented by HMP Communications, the publishers of OWM, WOUNDS, Today's Wound Clinic, Podiatry Today and producers of the Symposium on Advanced Wound Care. The seminar will be attended by podiatrists, nurses, PT's, nursing home administrators, dieticians, and pharmacists who care for patients with wounds. The focus is on the clinical and economic perspective of wound care delivery in various sites of service.

Two middle-aged men presented with diabetic wounds to the lower extremities arising from minor incidental trauma and/or venous stasis disease; the wounds were chronic in nature and refractory to standard treatment. This short case study aims to examine the use of fragmented, activated, type I collagen in treating these wounds. The authors have used this short case study to stimulate a larger, currently ongoing study. The collagen provided and used in the treatment of these patients was in the powder-and-gel form of CellerateRx (Wound Care Innovations, LLC, Fort Lauderdale, Florida) and was provided by the manufacturer, The Hymed Group. CellerateRx is cleared by the US Food and Drug Administration to treat diabetic and nondiabetic wounds, Stages II-IV pressure ulcers, ulcers resulting from venous stasis and arterial insufficiency, traumatic wounds, and superficial and surgical wounds, including superficial and partial-thickness burns (excluding full-thickness burns). The collagen molecules found in this product are 1/100th of the size of naturally occurring collagen and present more surface area. Thus, the patient can benefit from the collagen more quickly.

For the complete article, click here.

Wound Care Innovations, LLC, a subsidiary of Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM - News), announced today that it will be presenting at the Georgetown University Hospital's Team Approach to Diabetic Limb Salvage (DLS) conference in Washington DC September 18th-20th. The conference is intended to better equip each member of the team with the resources needed to heal wounds and prevent amputations. "We are delighted to be exhibiting at the DLS conference," states Cathy Bradshaw, President of Wound Care Innovations.

Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM - News), announced today its strategic plans for the remainder of the year and for 2009. "The company has been focused on bringing the science and technology to the market for the first 3 quarters of the year to position CellerateRx(TM) as the number one collagen-based wound care product in the world. We have been working with several major medical groups, physicians and scientists across the US to validate our belief that CellerateRx is a 'one-of-a-kind' collagen product," stated CEO Scott Haire.

Wound Care Innovations, LLC, a subsidiary of Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM - News), announced today that it will be presenting at the New Cardiovascular Horizons and Management of the Diabetic Foot & Wound Healing (NCVH) conference in New Orleans September 10-13. NCVH is one of the largest multidisciplinary conferences in the country bringing together the leaders in the wound care market place. There are over 3500 expected attendees and one of the most distinguished faculty lists in the wound care industry. One of the featured speakers is Dr.

Zangani Investor Community interviews Cathy Bradshaw, President of Wound Care Innovations, LLC. Cathy discusses a recent agreement between Wound Management Technologies and Dr. Leland Shapiro, MD to conduct studies on their advanced wound care collagen product, CellerateRx(R).

Wound Care Innovations, LLC, a subsidiary of Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM - News), announced today that Cathy Bradshaw, President, was interviewed by the Zangani Investor Community on their advanced wound care collagen product, CellerateRx®. Ms. Bradshaw briefly discussed some of the recent announcements of the company, distinguishing unique product characteristics and plans for international distribution. "It was a pleasure to be interviewed by the Zangani Investor Community," states Cathy Bradshaw. "We are excited about the recent agreement with Dr.

Wound Care Innovations, LLC, a subsidiary of Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM - News), announced today that it has signed an agreement with Dr. Leland Shapiro, MD to conduct studies on their advanced wound care collagen product, CellerateRx®. Dr. Shapiro, Associate Professor of Medicine at the University of Colorado Denver School of Medicine and the Denver Veteran's Affairs Medical Center, has published extensively on factors affecting cell cytokine induction and suppression.

Wound Care Innovations, LLC, a subsidiary of Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM - News), is excited about expanding upon the announcement that was made on Tuesday regarding the publication of (2) independent case reports utilizing their advanced wound care collagen product, CellerateRx®, in the August edition of Advances in Skin and Wound Care. The case presentations were on recalcitrant diabetic wounds. The article will be available in its entirety for viewing on the company website, www.celleraterx.com in two weeks.

Wound Care Innovations, LLC, a subsidiary of Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM - News), announced today the publication of (2) independent case reports utilizing their advanced wound care collagen product, CellerateRx®, in the August edition of Advances in Skin and Wound Care. The case presentations were on recalcitrant diabetic wounds. "Many factors have been implicated in the problematic nature of diabetic wounds to the lower extremities," states Cathy Bradshaw, President of Wound Care Innovations.

Wound Care Innovations, LLC, a subsidiary of Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM - News), announced today that it has entered into a confidentiality agreement with a company to register and distribute their advanced wound care collagen products, CellerateRx®, in Taiwan. "We have had a tremendous response and inquiries from the international community about CellerateRx®," states Cathy Bradshaw, President of Wound Care Innovations.

Wound Care Innovations, LLC, a subsidiary of Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM - News), announced today an evidence based study with a NE podiatric clinic evaluating the clinical performance of their advanced wound care collagen product, CellerateRx®, on diabetic venous ulcers. "According to data released by the Centers for Disease Control and Prevention, diabetes now affects nearly 24 million people in the United States alone," states Cathy Bradshaw, President of Wound Care Innovations.

Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM - News), announced today the filing of a new 510K on a new wound management product utilizing their patented hydrolyzed collagen technology.

Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM - News), has announced the signing of a commission based, sales agreement for its wound care product, CellerateRx®, with EWA Government Systems, Inc. (EWA GSI). This agreement follows discussions and demonstrations, and validates that CellerateRx is destined to play a vital role in international wound management. CellerateRx patented collagen fragments (CRX) are a fraction of the size of native collagen molecules found in other products, and provide the benefits of collagen to the body immediately.

MB Software Corporation (OTC Bulletin Board: MBSB - News) announced today that Company's new symbol will be (OTC Bulletin Board: WNDM - News). This change was made by the OTCBB to reflect the Company's new name, Wound Management Technologies, Inc. The company is also announcing that the Company's Vice President of Corporate Development, Cathy Bradshaw, will move to the position of President of Wound Care Innovations, LLC. The firm is also currently in the process of searching for an Advisory Board and Board of Directors as it develops its to market strategy for Cellerate Rx.